Executives at the British drug maker GlaxoSmithKline were warned nearly two years ago about critical problems with the way the company conducted research at its drug development center in China, exposing it to potential financial risk and regulatory action, an internal audit found.
Drug research in China falls under a cloud
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.